AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF) announced Tuesday they have withdrawn the EU marketing application ...

For Q3 2024, the equity sleeve of the Voya Asia Pacific High Dividend Equity Income Fund underperformed its reference Index.

It's time to look towards 2025 after another banner year for stocks. Click here to read more about four stocks to keep on the ...

Sharp Corporation is transitioning from high-investment, competitive segments to faster-growing, less competitive ones. Read ...

XAR's diversified portfolio of fast-growing mid- and small-caps makes it a compelling investment. See why the Fund is a Buy.

NNN REIT has declined abruptly in the past month, largely due to systematic factors. Learn why NNN stock is a Buy.

After almost two decades of stagnant growth, U.S. electricity demand is projected to increase from 4,012 terawatt hours in ...

Lufax's solid balance sheet and undervaluation suggest significant room for stock price improvement. Learn why LU stock is a ...

For the third quarter of 2024, the Voya Small Cap Growth Strategy underperformed its benchmark. Click here to read the full ...

I reiterate a hold rating for ZoomInfo Technologies due to near-term headwinds despite medium-term growth potential from ...

For Q3 2024, the Voya Emerging Markets High Dividend Equity Fund provided a total return of 6.42% on a NAV basis. Click here ...

Camden is a strong investment option with a history of growth and consistent dividends, despite potential risks and ...